Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated japanese patients with early rheumatoid arthritis

52-week results of the hopeful-1 trial

Hisashi Yamanaka, Naoki Ishiguro, Tsutomu Takeuchi, Nobuyuki Miyasaka, Masaya Mukai, Tsukasa Matsubara, Shoji Uchida, Hideto Akama, Hartmut Kupper, Vipin Arora, Yoshiya Tanaka

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: The aim of this study was to compare efficacy outcomes of initial treatment with adalimumab + MTX vs adalimumab addition following 26 weeks of MTX monotherapy in Japanese early RA patients naive to MTX with high disease activity. Methods: Patients completing the 26-week, randomized, placebo-controlled trial of adalimumab + MTX were eligible to receive 26 weeks of open-label adalimumab + MTX. Patients were assessed for mean change from baseline in the 28-joint DAS with ESR (DAS28-ESR) and modified total Sharp score (mTSS), and for the proportions of patients achieving clinical, functional or radiographic remission. Results: Of 333 patients assessed, 278 (137 from the initial adalimumab + MTX and 141 from the initial placebo + MTX groups) completed the 52-week study. Significant differences in clinical and functional parameters observed during the 26-week blinded period were not apparent following the addition of open-label adalimumab to MTX. Open-label adalimumab + MTX slowed radiographic progression through week 52 in both groups, but patients who received adalimumab + MTX throughout the study exhibited less radiographic progression than those who received placebo + MTX during the first 26 weeks (mean ΔmTSS at week 52 = 2.56 vs 3.30, P < 0.001). Conclusion: Delayed addition of adalimumab in Japanese MTX-naive early RA patients did not impact clinical and functional outcomes at week 52 compared with the earlier addition of adalimumab. However, the accrual of significant structural damage during blinded placebo + MTX therapy contributed to the persistence of differences between the treatment strategies, suggesting that Japanese patients at risk for aggressive disease should benefit from the early inclusion of adalimumab + MTX combination therapy.Trial registration. ClinicalTrials.gov (http://clinicaltrials.gov/), NCT00870467.

Original languageEnglish
Article numberket465
Pages (from-to)904-913
Number of pages10
JournalRheumatology (United Kingdom)
Volume53
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Methotrexate
Rheumatoid Arthritis
Placebos
amsonic acid
Adalimumab
Therapeutics
Randomized Controlled Trials
Joints

Keywords

  • Adalimumab
  • Japanese patients
  • MTX naive
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated japanese patients with early rheumatoid arthritis : 52-week results of the hopeful-1 trial. / Yamanaka, Hisashi; Ishiguro, Naoki; Takeuchi, Tsutomu; Miyasaka, Nobuyuki; Mukai, Masaya; Matsubara, Tsukasa; Uchida, Shoji; Akama, Hideto; Kupper, Hartmut; Arora, Vipin; Tanaka, Yoshiya.

In: Rheumatology (United Kingdom), Vol. 53, No. 5, ket465, 2014, p. 904-913.

Research output: Contribution to journalArticle

Yamanaka, Hisashi ; Ishiguro, Naoki ; Takeuchi, Tsutomu ; Miyasaka, Nobuyuki ; Mukai, Masaya ; Matsubara, Tsukasa ; Uchida, Shoji ; Akama, Hideto ; Kupper, Hartmut ; Arora, Vipin ; Tanaka, Yoshiya. / Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated japanese patients with early rheumatoid arthritis : 52-week results of the hopeful-1 trial. In: Rheumatology (United Kingdom). 2014 ; Vol. 53, No. 5. pp. 904-913.
@article{64dc3eb0f28b4a6f82edbd43fc3750b8,
title = "Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated japanese patients with early rheumatoid arthritis: 52-week results of the hopeful-1 trial",
abstract = "Objective: The aim of this study was to compare efficacy outcomes of initial treatment with adalimumab + MTX vs adalimumab addition following 26 weeks of MTX monotherapy in Japanese early RA patients naive to MTX with high disease activity. Methods: Patients completing the 26-week, randomized, placebo-controlled trial of adalimumab + MTX were eligible to receive 26 weeks of open-label adalimumab + MTX. Patients were assessed for mean change from baseline in the 28-joint DAS with ESR (DAS28-ESR) and modified total Sharp score (mTSS), and for the proportions of patients achieving clinical, functional or radiographic remission. Results: Of 333 patients assessed, 278 (137 from the initial adalimumab + MTX and 141 from the initial placebo + MTX groups) completed the 52-week study. Significant differences in clinical and functional parameters observed during the 26-week blinded period were not apparent following the addition of open-label adalimumab to MTX. Open-label adalimumab + MTX slowed radiographic progression through week 52 in both groups, but patients who received adalimumab + MTX throughout the study exhibited less radiographic progression than those who received placebo + MTX during the first 26 weeks (mean ΔmTSS at week 52 = 2.56 vs 3.30, P < 0.001). Conclusion: Delayed addition of adalimumab in Japanese MTX-naive early RA patients did not impact clinical and functional outcomes at week 52 compared with the earlier addition of adalimumab. However, the accrual of significant structural damage during blinded placebo + MTX therapy contributed to the persistence of differences between the treatment strategies, suggesting that Japanese patients at risk for aggressive disease should benefit from the early inclusion of adalimumab + MTX combination therapy.Trial registration. ClinicalTrials.gov (http://clinicaltrials.gov/), NCT00870467.",
keywords = "Adalimumab, Japanese patients, MTX naive, Rheumatoid arthritis, Safety",
author = "Hisashi Yamanaka and Naoki Ishiguro and Tsutomu Takeuchi and Nobuyuki Miyasaka and Masaya Mukai and Tsukasa Matsubara and Shoji Uchida and Hideto Akama and Hartmut Kupper and Vipin Arora and Yoshiya Tanaka",
year = "2014",
doi = "10.1093/rheumatology/ket465",
language = "English",
volume = "53",
pages = "904--913",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated japanese patients with early rheumatoid arthritis

T2 - 52-week results of the hopeful-1 trial

AU - Yamanaka, Hisashi

AU - Ishiguro, Naoki

AU - Takeuchi, Tsutomu

AU - Miyasaka, Nobuyuki

AU - Mukai, Masaya

AU - Matsubara, Tsukasa

AU - Uchida, Shoji

AU - Akama, Hideto

AU - Kupper, Hartmut

AU - Arora, Vipin

AU - Tanaka, Yoshiya

PY - 2014

Y1 - 2014

N2 - Objective: The aim of this study was to compare efficacy outcomes of initial treatment with adalimumab + MTX vs adalimumab addition following 26 weeks of MTX monotherapy in Japanese early RA patients naive to MTX with high disease activity. Methods: Patients completing the 26-week, randomized, placebo-controlled trial of adalimumab + MTX were eligible to receive 26 weeks of open-label adalimumab + MTX. Patients were assessed for mean change from baseline in the 28-joint DAS with ESR (DAS28-ESR) and modified total Sharp score (mTSS), and for the proportions of patients achieving clinical, functional or radiographic remission. Results: Of 333 patients assessed, 278 (137 from the initial adalimumab + MTX and 141 from the initial placebo + MTX groups) completed the 52-week study. Significant differences in clinical and functional parameters observed during the 26-week blinded period were not apparent following the addition of open-label adalimumab to MTX. Open-label adalimumab + MTX slowed radiographic progression through week 52 in both groups, but patients who received adalimumab + MTX throughout the study exhibited less radiographic progression than those who received placebo + MTX during the first 26 weeks (mean ΔmTSS at week 52 = 2.56 vs 3.30, P < 0.001). Conclusion: Delayed addition of adalimumab in Japanese MTX-naive early RA patients did not impact clinical and functional outcomes at week 52 compared with the earlier addition of adalimumab. However, the accrual of significant structural damage during blinded placebo + MTX therapy contributed to the persistence of differences between the treatment strategies, suggesting that Japanese patients at risk for aggressive disease should benefit from the early inclusion of adalimumab + MTX combination therapy.Trial registration. ClinicalTrials.gov (http://clinicaltrials.gov/), NCT00870467.

AB - Objective: The aim of this study was to compare efficacy outcomes of initial treatment with adalimumab + MTX vs adalimumab addition following 26 weeks of MTX monotherapy in Japanese early RA patients naive to MTX with high disease activity. Methods: Patients completing the 26-week, randomized, placebo-controlled trial of adalimumab + MTX were eligible to receive 26 weeks of open-label adalimumab + MTX. Patients were assessed for mean change from baseline in the 28-joint DAS with ESR (DAS28-ESR) and modified total Sharp score (mTSS), and for the proportions of patients achieving clinical, functional or radiographic remission. Results: Of 333 patients assessed, 278 (137 from the initial adalimumab + MTX and 141 from the initial placebo + MTX groups) completed the 52-week study. Significant differences in clinical and functional parameters observed during the 26-week blinded period were not apparent following the addition of open-label adalimumab to MTX. Open-label adalimumab + MTX slowed radiographic progression through week 52 in both groups, but patients who received adalimumab + MTX throughout the study exhibited less radiographic progression than those who received placebo + MTX during the first 26 weeks (mean ΔmTSS at week 52 = 2.56 vs 3.30, P < 0.001). Conclusion: Delayed addition of adalimumab in Japanese MTX-naive early RA patients did not impact clinical and functional outcomes at week 52 compared with the earlier addition of adalimumab. However, the accrual of significant structural damage during blinded placebo + MTX therapy contributed to the persistence of differences between the treatment strategies, suggesting that Japanese patients at risk for aggressive disease should benefit from the early inclusion of adalimumab + MTX combination therapy.Trial registration. ClinicalTrials.gov (http://clinicaltrials.gov/), NCT00870467.

KW - Adalimumab

KW - Japanese patients

KW - MTX naive

KW - Rheumatoid arthritis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84898785888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898785888&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ket465

DO - 10.1093/rheumatology/ket465

M3 - Article

VL - 53

SP - 904

EP - 913

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 5

M1 - ket465

ER -